Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mothers against decapentaplegic homolog 7 mRNA (Smad7 mRNA)
- Target
- Smad7 mRNA
- Molecular classification
- mRNA transcript (messenger RNA of a protein-coding gene), Encodes a member of the "Smad family" (specifically, inhibitory Smads)
01
Overview
Smad7 mRNA encodes mothers against decapentaplegic homolog 7, a key intracellular inhibitory modulator of the TGF-β family signaling pathways through negative feedback on receptor-mediated Smad2/3 activation. Smad7 mRNA is the immediate target for antisense therapies (like Mongersen), and it plays major roles in controlling cellular proliferation, inflammation, apoptosis, and tissue homeostasis. The dysregulation of Smad7 is associated with pathologies such as cancer, autoimmunity, chronic inflammation, fibrotic disease, and cardiovascular development. Therefore, Smad7 mRNA serves as a molecular target for various potential therapeutic interventions and a biomarker for disease progression and treatment efficacy
- Other names
- MADH7 mRNASmad7 transcriptI-Smad7 mRNA
02
Mechanism of action
RNA-based drugs: Antisense oligonucleotides bind Smad7 mRNA, leading to its degradation and decreased Smad7 protein expression; this restores TGF-β signaling activity
03
Biological functions
Negative regulation of TGF-β (transforming growth factor-beta) signalingInhibition of cell proliferationModulation of apoptosisRegulation of immune responses and inflammationRegulation of cell differentiationNegative feedback for TGF-β, activin, and BMP (bone morphogenetic protein) pathways
04
Disease associations
Cancer (colorectal cancer, pancreatic cancer, others)InflammationAutoimmune diseasesFibrosisKidney diseasesCardiovascular disease (congenital heart defects)
05
Safety considerations
Targeting Smad7 mRNA may cause excessive TGF-β signaling, potentially resulting in fibrosis, immunosuppression, or adverse tissue remodelingTherapeutic balance is crucial, as both overexpression and insufficient expression of Smad7 are linked to disease
06
Interacting drugs
Mongersen (GED-0301; an antisense oligonucleotide targeting Smad7 mRNA in Crohn's disease)
07
Biomarkers
Smad7 mRNA expression (as a biomarker for TGF-β pathway activity, and for selection/monitoring in certain inflammatory diseases and cancer)
Beyond the preview
Go deeper on Mothers against decapentaplegic homolog 7 mRNA (Smad7 mRNA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mothers against decapentaplegic homolog 7 mRNA (Smad7 mRNA).